CMAC’s vision is to revolutionise the way pharmaceuticals and high value products are made. The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Bayer, Lilly, Novartis, Pfizer, Roche and Takeda. Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, post docs, and more than 45 PhD students, as well as an experienced support team.
3rd International Symposium on Continuous Manufacturing of Pharmaceuticals took place at the Grange Hotel in London 3-4 October 2018. .... more
CCDC Joins CMAC as Tier 2 Partner
The Cambridge Crystallographic Data Centre (CCDC) has joined CMAC as a Tier 2 Member in order to equip scientists in the field of pharmaceutical manufacturing with the tools required to master their structural data. .... more
Accelerating the delivery of new drugs to patients
A project aimed at accelerating the delivery of new drugs to patients, led by the University of Strathclyde and Glasgow School of Art, has received a grant of £1.9 million..... more